"Novo Nordisk's Breakthrough Obesity Drug Outperforms Competitors in Early Trials"

Novo Nordisk's early trial data for its experimental obesity drug amycretin showed a higher weight loss compared with its popular Wegovy treatment, with participants losing 13.1% of their weight after 12 weeks compared to 6% for Wegovy. The company's shares surged to a record peak following the announcement, indicating investor confidence in its pipeline beyond Wegovy. Novo also announced plans to expand its focus on diabetes and weight-loss therapies to include cardiovascular disease treatments.